Although the presence of a slightly compromised BBB in some patients suffering from these neuropsychiatric diseases is well established and allows a higher quantity of EPO to reach the brain (Ehrenreich et al. 2004), it is unlikely equivalent to the massive BBB breakdown expected in severe COVID-19 with the typical cytokine storm. Here, EPO is linked to COVID-19.